PharmTech Drug Digest 11.20
News|Articles|November 10, 2015

UK Center Installs Protein Purification Technology

The UK’s National Biologics Manufacturing Centre will use Novasep’s BioSC Lab for protein purification.

The Centre for Process Innovation (CPI), a UK-based technology innovation center that provides services to small and medium-sized enterprises in the UK, has equipped the UK National Biologics Manufacturing Centre with Novasep’s BioSC Lab for protein purification. CPI’s services are intended to decrease time to market for novel products or processes. Within this framework, the CPI has been keen to introduce breakthrough continuous processes in the UK biopharmaceutical sector, CPI said in a press release. These technologies enable developers to reduce equipment footprint and increase process yields, thereby saving time and money.

“The National Biologics Manufacturing Centre has been designed to help companies of all sizes to develop, prove, and commercialize new and improved processes and technologies for biopharmaceutical manufacture,” said Chris Dowle, director of biologics at CPI, in the release. “The installation of Novasep’s BioSC Lab will be a valuable asset to customers using the centre."

Novasep’s continuous biochromatography equipment, BiosSC Lab, can purify a few grams of proteins per day. This enables users to develop cost-effective, high-yield production processes while maintaining the same quality attributes of the protein. The equipment is flexible and supports any process operating mode, including batch, parallel batch, and continuous. It is specifically designed to quickly provide the operator with the best operational parameters for purifying and converting a batch biochromatography recipe into a continuous, optimized one. Its simulation software, BioSC Predict, frees the process developer to set the most efficient mode and parameters to purify biomolecules such as monoclonal antibodies (mAbs), blood factors, and other proteins.

Source: Novasep


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.